Physicians Realty Trust - DOC Stock Forecast, Price & News

Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing high quality healthcare. The Company conducts its business through an UPREIT structure in which its properties are owned by Physicians Realty L.P., a Delaware limited partnership (the operating partnership), directly or through limited partnerships, limited liability companies or other subsidiaries. The Company is the sole general partner of the operating partnership and, as of September 30, 2020, owned approximately 97.4% of OP Units.

Physicians Realty Trust Stock Performance

Shares of DOC opened at $18.09 on Thursday. Physicians Realty Trust has a 52 week low of $16.07 and a 52 week high of $19.30. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.65. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of 51.69, a PEG ratio of 2.93 and a beta of 0.79. The business has a 50-day simple moving average of $17.26 and a two-hundred day simple moving average of $17.41.

Physicians Realty Trust Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, July 19th. Stockholders of record on Tuesday, July 5th were paid a $0.23 dividend. The ex-dividend date of this dividend was Friday, July 1st. This represents a $0.92 dividend on an annualized basis and a dividend yield of 5.09%. Physicians Realty Trust's dividend payout ratio (DPR) is presently 262.86%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Jefferies Financial Group lowered their price target on Physicians Realty Trust from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, June 30th. Colliers Securities downgraded shares of Physicians Realty Trust from a "buy" rating to a "neutral" rating and set a $19.00 price objective on the stock. in a research report on Friday, August 5th. TheStreet downgraded shares of Physicians Realty Trust from a "b-" rating to a "c+" rating in a research report on Tuesday, June 28th. Morgan Stanley lowered their price target on Physicians Realty Trust from $17.50 to $16.00 and set an "equal weight" rating on the stock in a report on Friday, July 15th. Finally, Bank of America downgraded Physicians Realty Trust from a "neutral" rating to an "underperform" rating and set a $18.00 price target on the stock. in a research note on Thursday, May 19th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $18.70.

Insider Activity

In other Physicians Realty Trust news, Director Pamela Shelley-Kessler purchased 3,000 shares of the firm's stock in a transaction on Tuesday, June 14th. The shares were acquired at an average cost of $16.81 per share, with a total value of $50,430.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at $50,430. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Physicians Realty Trust news, CEO John T. Thomas sold 10,000 shares of Physicians Realty Trust stock in a transaction on Monday, August 15th. The shares were sold at an average price of $18.15, for a total value of $181,500.00. Following the sale, the chief executive officer now directly owns 499,801 shares in the company, valued at approximately $9,071,388.15. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Pamela Shelley-Kessler acquired 3,000 shares of the company's stock in a transaction on Tuesday, June 14th. The shares were bought at an average cost of $16.81 per share, with a total value of $50,430.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at $50,430. The disclosure for this purchase can be found here. Insiders have sold 24,330 shares of company stock worth $439,460 in the last three months. Company insiders own 0.89% of the company's stock.